natgillin/translations-raw huggingface dataset:
EFV = efavirenz, FTC = emtricitabin, TDF = tenofovirdisoproxilfumarat, E/C/F/TDF = elvitegravir/cobicistat/emtricitabin/tenofovirdisoproxilfumarat a Uge 48-vinduet var fra dag 294 til 377 (inklusive).
EFV = efavirenz; FTC = emtricitabine; TDF = tenofovir disoproxil fumarate; E/C/F/TDF = elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate a Week 48 window was between Day 294 and 377 (inclusive).
EFV/TDF/FTC = 600 mg efavirenz, 300 mg tenofovir, 200 mg emtricitabin i form af fastdosiskombinationen (FDC) Atripla.
EFV/TDF/FTC = efavirenz 600 mg, tenofovir 300 mg, emtricitabine 200 mg in the form of Atripla FDC.
Egen FPG-måling
Self­measured FPG
Egenskaber hos forskellige patientgrupper
Characteristics of different patient groups
Egenskaber hos ældre patienter:
Characteristics in elderly patients
Egentlige farmakokinetiske studier hos ældre og hos patienter med nedsat nyre- eller leverfunktion er ikke udført.
Dedicated pharmacokinetic studies in the elderly and those with renal or hepatic impairment have not been carried out.
Egenundersøgelse af Deres/din eller Deres/dit barns hud anbefales.
Self examination of your or your child’s skin is recommended.
EGFR aktiverer proteiner kaldet RAS.
EGFR activates proteins called RAS.
eGFR ≥60 til <90 ml/min/1,73 m²
eGFR ≥60 to <90 ml/min/1.73 m²
EGFR- aktiverede mutationer i cancerceller er en vigtig, understøttende faktor ved tumorcellevækst, blokering af apoptose, forøgelse af produktionen af angiogene faktorer og facilitering af metastaseprocesser.
EGFR activating mutation within a cancer cell is an important factor in promotion of tumour cell growth, blocking of apoptosis, increasing the production of angiogenic factors and facilitating the processes of metastasis.
EGFR-ekspressionen er kendt hos 45 % af patienterne.
In the 45% of patients with known EGFR-expression status, the hazard ratio was 0.68 (95
eGFR-forbedring ≥ 15 ml/min/1,73m2
eGFR improvement ≥ 15 mL/min/1.73m2
eGFR-forbedring ≥15 ml/min/ 1,73•m2, n (%)
eGFR improvement ≥15 mL/min/ 1.73•m2, n (%)
EGFR-mutation ukendt
EGFR mutation
EGFR-mutation+ EGFR-mutation- Har aldrig røget
EGFR Mutation+ EGFR Mutation- Never-smoker Ever-smoker Adenocarcinoma
eGFR-ændring ml/min/1,73m2, median
eGFR change mL/min/1.73 m2: median (range)
eglcelleanæmi,
ickle cell anaemia;
eglcelleanæmi;
ickle cell anaemia;
Egnede fortyndingsmidler
Compatible Infusion Solutions:
Egnede infusionsopløsninger omfatter: dextrose 50 mg/ml (5 %) injektionsvæske, opløsning, natriumchlorid 9 mg/ml (0,9 %) injektionvæske, opløsning, eller Ringer-laktat injektionsvæske, opløsning.
Appropriate infusion solutions include: dextrose 50 mg/ml (5%) solution for injection, sodium chloride 9 mg/ml (0.9%) solution for injection or lactated Ringer’s solution for injection.
Egnede patienter blev randomiseret i forholdet 1:1 til at få enten Empliciti i kombination med lenalidomid og dexamethason eller lenalidomid og dexamethason.
Eligible patients were randomised in a 1:1 ratio to receive either Empliciti in combination with lenalidomide and dexamethasone or lenalidomide and dexamethasone.
Egnede patienter havde fået kemoterapi mod malignitet eller havde fået hæmatopoietisk stamcelle transplantation, og havde neutropeni (<500 celler/mm3 i 96 timer) og havde haft feber (>38,0 °C) uden respons i mere end 96 timer til parenteral antibakteriel behandling.
Eligible patients had received chemotherapy for malignancy or had undergone hematopoietic stem-cell transplantation, and presented with neutropaenia (<500 cells/mm3 for 96 hours) and fever (>38.0°C) not responding to ≥96 hours of parenteral antibacterial therapy.
Egnede patienter havde oplevet multiple astmaeksacerbationer, der krævede behandling med systemisk kortikosteroid, eller havde været indlagt på hospitalet eller fået behandling på en skadestue på grund af en svær astmaeksacerbation i det sidste år på trods af kontinuerlig behandling med højdosis- inhalationskortikosteroider og en langtidsvirkende beta2-agonist.
Eligible patients had experienced multiple asthma exacerbations requiring systemic corticosteroid treatment or had been hospitalised or attended an emergency room due to a severe asthma exacerbation in the past year despite continuous treatment with high-dose inhaled corticosteroids and a long-acting beta2-agonist.
Egnede patienter på en stabil dosis af 1 til 3 AED'er, der oplevede mindst 3 primært generaliserede tonisk-kloniske anfald i løbet af den 8- ugers baselineperiode, blev randomiseret til enten perampanel eller placebo.
Eligible patients on a stable dose of 1 to 3 AEDs experiencing at least 3 primary generalised tonic-clonic seizures during the 8-week baseline period were randomised to either perampanel or placebo.
Egnede teknikker til selvadministration af Stelara, inklusive brug af den fyldte injektionssprøjte.
Appropriate techniques for self administration of Stelara, including use of the prefilled syringes.
Egnet til effektanalyse, n
Eligible for efficacy analysis, n
EID50 - 50% embryo infective dose: den virustiterværdi, som er nødvendig for at forårsage infektion i 50% af de inokulerede embryoner.
EID50: 50% embryo infective dose - the titre required to infect 50% of the embryos inoculated with the virus.
EID50 - 50% embryo infective dose: Den virustiterværdi, som er nødvendig for at forårsage infektion i 50% af de inokulerede embryoner.
EID50: 50% embryo infective dose - the virus titre required to produce infection in 50% of the embryos inoculated.
EID50 pr. dosis
EID50 per dose
Eimeria acervulina, stamme 003 - 332 – 450 sporulerede oocyster
Eimeria acervulina, strain 003 - 332–450 sporulated oocysts
Eimeria acervulina, stamme 003 332 – 450
Eimeria acervulina, strain 003 332–450
Eimeria brunetti, stamme 034 - 213 – 288 sporulerede oocyster
Eimeria brunetti, strain 034 - 213–288 sporulated oocysts
Eimeria brunetti, stamme 034 213 – 288
Eimeria brunetti, strain 034 213–288
Eimeria maxima, stamme 013 - 196 – 265 sporulerede oocyster
Eimeria maxima, strain 013 - 196–265 sporulated oocysts
Eimeria maxima, stamme 013 196 – 265
Eimeria maxima, strain 013 196–265
Eimeria necatrix, stamme 033 - 340 – 460 sporulerede oocyster
Eimeria necatrix, strain 033 - 340–460 sporulated oocysts
Eimeria necatrix, stamme 033 340 – 460
Eimeria necatrix, strain 033 340–460
Eimeria tenella, stamme 004 - 276 – 374 sporulerede oocyster
Eimeria tenella, strain 004 - 276–374 sporulated oocysts
Eimeria tenella, stamme 004 276 – 374
Eimeria tenella, strain 004 276–374
Einsteinweg 101
Special populations
Eisai Europe Limited, European Knowledge Centre, Mosquito Way, Hatfield, Hertfordshire, AL10 9SN, Storbritannien e-mail: EUmedinfo@eisai.net
Eisai Europe Limited, European Knowledge Centre, Mosquito Way, Hatfield, Hertfordshire, AL10 9SN, United Kingdom e-mail: EUmedinfo@eisai.net
Eisai Europe Limited, European Knowledge Centre, Mosquito Way, Hatfield, Herts AL10 9SN, Storbritannien
Eisai Europe Limited, European Knowledge Centre, Mosquito Way, Hatfield, Herts AL10 9SN, United Kingdom
Eisai Limited, European Knowledge Centre, Mosquito Way, Hatfield, Hertfordshire, AL10 9SN, Storbritannien
Eisai Limited, European Knowledge Centre, Mosquito Way, Hatfield, Hertfordshire, AL10 9SN, UK
Eisai Limited, European Knowledge Centre, Mosquito Way, Hatfield, Hertfordshire, AL10 9SN, Storbritannien.
Eisai Ltd, European Knowledge Centre, Mosquito Way, Hatfield, Hertfordshire, AL10 9SN, UK.
Eisai Ltd, European Knowledge Centre, Mosquito Way, Hatfield, Hertfordshire, AL10 9SN, Storbritannien.
Eisai Ltd, European Knowledge Centre, Mosquito Way, Hatfield, Hertfordshire AL10 9SN, UK.
Eisai Ltd., European Knowledge Centre, Mosquito Way, Hatfield, Hertfordshire, AL10 9SN, Storbritannien
Eisai Limited, European Knowledge Centre, Mosquito Way, Hatfield, Hertfordshire, AL10 9SN, UK
Eisai Ltd., European Knowledge Centre, Mosquito Way, Hatfield, Hertfordshire, AL10 9SN, Storbritannien.
Eisai Ltd, European Knowledge Centre, Mosquito Way, Hatfield, Hertfordshire, AL10 9SN, UK.
Eisai Ltd., European Knowledge Centre, Mosquito Way, Hatfield, Hertfordshire, AL10 9SN, Storbritannien.
Eisai Ltd., European Knowledge Centre, Mosquito Way, Hatfield, Hertfordshire, AL10 9SN, UK.
Eisai Ltd., European Knowledge Centre, Mosquito Way, Hatfield, Herts AL10 9SN, Storbritannien
Eisai Ltd., European Knowledge Centre, Mosquito Way, Hatfield, Herts AL10 9SN, United Kingdom
Eisai Ltd., European Knowledge Centre, Mosquito Way, Hatfield, Herts AL10 9SN, Storbritannien.
Eisai Ltd., European Knowledge Centre, Mosquito Way, Hatfield, Herts AL10 9SN, United Kingdom.
Eisai Ltd., European Knowledge Centre, Mosquito Way, Hatfield, Herts AL10 9SN, Storbritannien. e-mail: EUmedinfo@eisai.net.
Eisai Ltd., European Knowledge Centre, Mosquito Way, Hatfield, Herts AL10 9SN, United Kingdom. e-mail: EUmedinfo@eisai.net
Eisai Manufacturing Ltd, European Knowledge Centre,Mosquito Way, Hatfield, Herts AL10 9SN, Storbritannien.
Eisai Manufacturing Ltd, European Knowledge Centre, Mosquito Way, Hatfield, Herts AL10 9SN, United Kingdom.
Eisai Manufacturing Ltd, Mosquito Way, Hatfield, Hertfordshire AL10 9SN, Storbritannien.
Eisai Manufacturing Ltd, Mosquito Way, Hatfield, Hertfordshire AL10 9SN, UK.
Eisai Manufacturing Ltd, Mosquito Way, Hatfield, Hertfordshire, AL10 9SN, Storbritannien
Eisai Manufacturing Ltd, Mosquito Way, Hatfield, Hertfordshire, AL10 9SN, UK
Eisai Manufacturing Ltd, Mosquito Way, Hatfield, Herts AL10 9SN, Storbritannien.
Eisai Manufacturing Ltd, Mosquito Way, Hatfield, Herts AL10 9SN, United Kingdom.
Ej relevant
Not applicable
Ej udfyldt
No entry
ejakulation
delayed
Ejakulations-
Ejaculation
Ejakulations- forstyrrelser, herunder retrograd ejakulation Anejakulation
Ejaculatory disorders, including retrograde ejaculation, anejaculation
Ejeren af markedsføringstilladelsen er TMC Pharma Services Ltd.
The marketing authorisation holder is TMC Pharma Services Ltd.
ek
ecs
ek
secs
ekale alkaloider (f.eks. ergotamin, dihydroergotamin, ergonovin og methylergonovin) (risiko for akut sekale-toksicitet)
ergot alkaloids (e.g. ergotamine, dihydroergotamine, ergonovine, and methylergonovine) (potential for acute ergot toxicity)
ekalealkaloider (f.eks. dihydroergotamin, ergometrin, ergotamin, methylergometrin)
ergot derivatives (e.g. dihydroergotamine, ergometrine, ergotamine, methylergonovine)
ekalealkaloider (f.eks. ergotamin, dihydroergotamin, ergonovin og methylergonovin) (mod migræne og klyngehovedpine)
Ergot alkaloids (for example, ergotamine, dihydroergotamine, ergonovine, and methylergonovine) (used to treat migraine and cluster headaches)
ekalealkaloider (f.eks. ergotamin, dihydroergotamin, ergonovin og methylergonovin) (risiko for akut sekale-toksicitet)
ergot alkaloids (e.g. ergotamine, dihydroergotamine, ergonovine, and methylergonovine) (potential for acute ergot toxicity)
ekalealkaloider (fx ergotamin, dihydroergotamin, ergonovin og methylergonovin) (mod migræne og klyngehovedpine)
ergot alkaloids (for example, ergotamine, dihydroergotamine, ergonovine, and methylergonovine) (used to treat migraine and cluster headaches)
ekalealkaloider (fx ergotamin, dihydroergotamin, ergonovin og methylergonovin) (mod migræne og klyngehovedpine).
ergot alkaloids (for example, ergotamine, dihydroergotamine, ergonovine, and methylergonovine) (used to treat migraine and cluster headaches)
ekalealkaloider (medicin mod hovedpine)
ergot derivatives (used to treat headaches)
ekalealkaloider (medicin mod migræne)
ergot derivatives (used to treat headaches)
ekalealkaloider (til behandling af migræne)
ergot derivatives (used to treat headaches)
ekalealkaloider - anvendes til behandling af migræneanfald
ergot alkaloids - for migraine attacks
ekalealkaloider - anvendes til behandling af migræneanfald
ergot alkaloids – for migraine attacks
ekalealkaloider og
Invirase/ritonavir and ergot alkaloids
ekalealkaloider og
Invirase/ritonavir and other proton
ekalealkaloider og som en konsekvens af
alkaloids exposure, and consequently,
EKG eller ekkokardiografi) for tegn på kardiovaskulære virkninger, der kan kræve yderligere kardiovaskulær undersøgelse.
ECG or echocardiography) for evidence of cardiovascular effects that may require further cardiovascular examination and investigation.
EKG inden for 24 timer, for at fastslå QTc-forlængelse.
ECG within 24 hours to determine QTc prolongation.
EKG QTc- forlængelse synes at være dosisafhængig.
ECG QTc prolongation appears to be dose-dependent.
EKG QTc-intervalforlængelse er identificeret som det største sikkerhedsproblem ved behandling med delamanid (se også 4.4).
Electrocardiogram QTc interval prolongation has been identified as the most prominent safety concern of treatment with delamanid (see also section 4.4).
EKG'er og blodprøver bør også indhentes som klinisk indiceret i løbet af denne periode og senere.
ECGs and blood tests should also be obtained as clinically indicated during this period and afterwards.
Ekg-forandringer (så som klinisk betydningsfuld sinusarrest, komplet hjerteblok, nyt grenblok, signifikant forlængelse af QRS- eller QT-intervallet, forandringer i overensstemmelse med iskæmi eller infarkt og ventrikulær arytmi).
ECG changes (such as a clinically meaningful sinus pause, complete heart block, new bundle branch block, significant prolongation of the QRS or QT interval, changes consistent with ischaemia or infarction and ventricular arrhythmia)
EKG-monitorering i hele
delamanid with
EKG-monitorering tilrådes, når der samtidig gives et lægemiddel, der er kendt for at forlænge QTc- intervallet (se pkt.
In case of co-administration of an agent known to increase QTc interval (see section 4.5), ECG monitoring is recommended.
Ekkymose
Pain in extremity
ekkymose (blodudtræden, der skyldes blødning fra ødelagte blodkar i huden).
ecchymosis (a small bruise caused by blood leaking from broken blood vessels in the skin)
ekkymose (blodudtræden, der skyldes blødning fra ødelagte blodkar i huden).
ecchymosis (a small bruise caused by blood leaking from broken blood vessels in the skin).
ekkymose (stort blodansamling)
ecchymosis (large skin hematoma)
Ekkymose eller hævelser‡ ved injektionsstedet, udslæt ved injektionsstedet‡
Ecchymosis or Swelling‡ at the injection site, injection-site rash
Ekkymose på injektionsstedet
Injection site ecchymosis
Ekkymose*
Ecchymosis
Ekkymose***
67 (20.9)
Ekkymose***
Ecchymosis
Ekkymose, blodudtrædning under huden
Ecchymosis, Skin haemorrhage
ekkymose, bulløs erruption, exfoliativ dermatitis, erythema multiforme, Stevens- Johnsons syndrom, toksisk epidermal nekrolyse, angioødem
Ecchymosis, bullous eruption, exfoliative dermatitis, erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis, angioedema
ekkymose, pruritus
ecchymosis, pruritus
Eklampsi og alvorlig præeklampsi, som kræver forløsning
Eclampsia and severe pre-eclampsia requiring delivery
Eklira Genuair 322 mikrogram inhalationspulver Aclidinium (aclidiniumbromid)
Eklira Genuair 322 micrograms inhalation powder Aclidinium (aclidinium bromide)
Eklira Genuair 322 µg inhalationspulver Aclidinium (aclidiniumbromid)
Eklira Genuair 322 mcg inhalation powder Aclidinium (aclidinium bromide)
Eklira Genuair anvendes til at lindre symptomerne ved kronisk obstruktiv lungesygdom (KOL) hos voksne.
Eklira Genuair is used to relieve the symptoms of chronic obstructive pulmonary disease (COPD) in adults.
Eklira Genuair er et hvidt eller næsten hvidt pulver.
Eklira Genuair is a white or almost white powder.
Eklira Genuair er et lægemiddel, der indeholder det aktive stof aclidiniumbromid.
Eklira Genuair is a medicine that contains the active substance aclidinium bromide.
Eklira Genuair er ikke beregnet til brug hos børn eller teenagere under 18 år.
Eklira Genuair is not for use in children or adolescents below 18 years of age.
Eklira Genuair er indiceret som bronkodilaterende vedligeholdelsesbehandling til lindring af symptomer hos voksne patienter med kronisk obstruktiv lungesygdom (KOL).
Eklira Genuair is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).
Eklira Genuair kan i mindre grad påvirke evnen til at føre motorkøretøj eller betjene maskiner.
Eklira Genuair may have minor influence on the ability to drive and use machines.
Eklira Genuair må ikke anvendes til personer, som er overfølsomme (allergiske) over for aclidiniumbromid, atropin, andre relaterede antikolinerge bronkodilatorer eller et af de øvrige indholdsstoffer.
Eklira Genuair must not be used in people who are hypersensitive (allergic) to aclidinium bromide, atropine, other related anticholinergic bronchodilator medicines, or any of the other ingredients.
Eklira Genuair reducerede signifikant hyperinflation under hvile (funktionel residualkapacitet [FRC]=0,197 l [95 % CI=0,321-0,072; p=0,002]; residualvolumen [RV]=0,238 l [95 % CI=0,396-0,079; p=0,004]) og forbedrede også inhalationskapaciteten (forbedrede dalværdien med 0,078 l; 95 % CI=0,01-0,145; p=0,025) og reducerede dyspnø i forbindelse med motion (Borg-skalaen) (med 0,63 Borg-enheder; 95
Eklira Genuair statistically significantly reduced lung hyperinflation at rest (functional residual capacity [FRC]=0.197 L [95% CI=0.321, 0.072; p=0.002]; residual volume [RV]=0.238 L [95% CI=0.396, 0.079; p=0.004]) and also improved trough inspiratory capacity (by 0.078 L; 95% CI=0.01, 0.145; p=0.025) and reduced dyspnoea during exercise (Borg scale) (by 0.63 Borg units; 95% CI=1.11, 0.14; p=0.012).
Eklira Genuair skal ikke anvendes ved astma; kliniske forsøg med aclidiniumbromid ved astma er ikke blevet udført.
Eklira Genuair should not be used in asthma; clinical trials of aclidinium bromide in asthma have not been conducted.
Eklira Genuair var mere effektivt end placebo til at forbedre lungefunktionen hos patienter med KOL.
Eklira Genuair was more effective than placebo at improving how well the lungs work in patients with COPD.
Eksacerba- tionskategori
Exacerbation Category
Eksacerbation af hjertelidelser som angina pectoris, kongestiv hjertesygdom eller svære hjertetilfælde (hjerteinsufficiens, myokardieinfarkt og atrieflimren), lungeødem, multiorgansvigt, tumorlysesyndrom, cytokinfrigivelsessyndrom, nyresvigt og respirationssvigt blev rapporteret med lavere eller ukendt hyppighed.
Exacerbations of pre-existing cardiac conditions such as angina pectoris or congestive heart failure or severe cardiac disorders (heart failure, myocardial infarction, atrial fibrillation), pulmonary oedema, multi-organ failure, tumour lysis syndrome, cytokine release syndrome, renal failure, and respiratory failure were reported at lower or unknown frequencies.
Eksacerbation eller udvikling af inflammatoriske/autoimmune sygdomme er beskrevet efter remission af Cushings syndrom, også efter behandling med ketoconazol.
Exacerbation or development of inflammatory/autoimmune disorders has been described after Cushing’s syndrome remission, including after treatment with ketoconazole.
Eksacerbation-reduktion studie (MEA115588) MENSA
Exacerbation reduction (MEA115588) MENSA study
eksacerbation:
exacerbation:
Eksacerbationer af hepatitis B efter behandlingsophør
Exacerbations of hepatitis B after discontinuation of treatment
Eksacerbationsrate pr. år
Exacerbation rate per year
Eksacerbationsrate pr. år
Exacerbations rate per year
Eksacerbationsrate/år
Exacerbation rate/year
eksantematøs pustulose
erectile dysfunction, gynaecomastia
eksantematøs pustulose*
exanthematous pustulosis
eksem
eczema
eksem
Eczema.
eksem (kløende røde pletter på huden)
eczema (itchy red patches on the skin)
Eksem Alopeci Pruritus
Eczema Alopecia Pruritus
Eksem Blister
Eczema Blister Erythema
eksem, erytem, hånddermatitis, psoriasis, generaliseret udslæt, kløende udslæt, neglelidelser
Eczema, erythema, hand dermatitis, psoriasis, rash generalised, rash pruritic, nail disorder
eksem, erytem, udslæt
eczema, erythema, rash
eksem, hævelser i ansigtet, eksfoliativt udslæt
eczema, swelling face, exfoliative rash
Eksem, rødme i huden
Eczema, redness of the skin
eksem, tør hud, udslæt, kløe,
eczema, dry skin, rash, itching,
Eksem, øget svedafsondring, rosacea
Eczema, increased sweating, rosacea
Eksema
Eczema
Eksempel Dosistæller stoppet:
Example Dose
Eksempel Dosisvinduet
Example
eksempel mandag-onsdag-fredag).
Monday-Wednesday-Friday).
Eksempel på en god forsegling Eksempel på en dårlig forsegling
Example of a good seal Example of a bad seal
Eksempel: For at opnå en genfinding på 0,8 IE/dl faktor IX, så:
Example: For a recovery of 0.8 IU/dL, the formula reads:
Eksempel: Hvis det endelige volumen er 20 ml, bør totaldoser af filgrastim på mindre end 30 ME (300 mikrogram) gives med tilsætning af 0,2 ml 200 mg/ml human serumalbuminopløsning (20 %).
Example: In a final injection volume of 20 ml, total doses of filgrastim less than 30 MU (300 micrograms) should be given with 0.2 ml of 200 mg/ml (20%) human albumin solution added.
Eksempel: Hvis din daglige dosis er 1.000 mg, er din lavere startdosis 2 tabletter på 250 mg om morgenen og 2 tabletter på 250 mg om aftenen.
Example: if your daily dose is 1000 mg, your reduced starting dose is 2 tablets of 250 mg in the morning and 2 tablets of 250 mg in the evening.
Eksempel: Ved en patient, der vejer 75 kg og har en clearance på 3 ml/time/kg, vil den initiale infusionshastighed være 3 IE/time/kg for at opnå et FVIII-niveau på 100%.
Example: for a 75 kg patient with a clearance of 3 mL/h/kg, the initial infusion rate would be 3 IU/h/kg to achieve a FVIII level of 100%.
Eksempel: Ved et 4-timers forbrug på 22 l og en doseringspumpeandel på 1 % behøves 22 l x 0,01 = 220 ml stamopløsning.
As an example, for a 4-hour consumption of 22 l and a dosing pump rate of 1%, the volume of the stock solution should be 22 l x 0.01 = 220 ml.
Eksempel: Ved et slut-injektionsvolumen på 20 ml og en totaldosis af filgrastim på mindre end 30 ME (300 mikrogram), skal det tilsættes 0,2 ml 200 mg/ml (20 %) human serumalbumin.
Example: In a final injection volume of 20 ml, total doses of filgrastim less than 30 MU (300 µg) should be given with 0.2 ml of 200 mg/ml (20%) human albumin solution added.
Eksempel: Ved et slutinjektionsvolumen på 20 ml og en totaldosis af filgrastim på mindre end 30 ME (300 mikrogram) skal det tilsættes 0,2 ml 200 mg/ml (20 %) human serumalbumin.
Example: In a final injection volume of 20 ml, total doses of filgrastim less than 30 MU (300 µg) should be given with 0.2 ml of 200 mg/ml (20%) human albumin solution added.
Eksempel: Ved et slutvolumen til injektion på 20 ml bør totaldoser af filgrastim på mindre end 30 mio.
Example: In a final injection volume of 20 ml, total doses of filgrastim less than 30 MIU (300 μg) should be given with
Eksempel: Ved et slutvolumen til injektion på 20 ml bør totaldoser af filgrastim på under 30 mio E (300 mikrogram) gives efter tilsætning af 0,2 ml 20 % human serumalbuminopløsning Ph.
Example: In a final injection volume of 20 ml, total doses of filgrastim less than 30 MU (300 micrograms) should be given with 0.2 ml of 20% human albumin solution added.
Eksempelvis er et brev med 40 g tilstrækkeligt til at behandle 1.000 fugle med en gennemsnitlig legemsvægt på 1 kg; 400 g tilstrækkeligt til at behandle 10.000 fugle med en gennemsnitlig legemsvægt på 1 kg.
For example, one sachet of 40 g is sufficient to treat a total of 1,000 birds with an average bodyweight of 1 kg; one sachet of 400 g is sufficient to treat a total of 10,000 birds with an average bodyweight of 1kg.
Eksempler findes nedenfor (men der er flere andre):
Examples are listed below (but there are several others):
Eksempler herpå er: sulfonamid- antibiotika, thiaziddiuretika og sulfonylurinstof-antidiabetika.
Examples include: sulfonamide antibiotics, thiazide diuretics, and sulfonylurea antidiabetes medicines.
Eksempler herpå er: sulfonamid- antibiotika, thiaziddiuretika og sulfonylurinstof-antidiabetika.
Examples include: sulphonamide antibiotics, thiazide diuretics, and sulfonylurea antidiabetes medicines.